Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright

Protara Therapeutics (NASDAQ:TARA)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $23.00 price target on the stock.

Separately, Oppenheimer lowered their price target on Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Monday, August 12th.

Protara Therapeutics Stock Down 4.3 %

Shares of NASDAQ:TARA opened at $2.47 on Thursday. The company’s fifty day moving average is $2.03 and its 200 day moving average is $2.29. Protara Therapeutics has a 52 week low of $1.04 and a 52 week high of $5.24. The stock has a market cap of $50.96 million, a PE ratio of -0.91 and a beta of 1.77.

Insider Activity at Protara Therapeutics

In other Protara Therapeutics news, major shareholder Opaleye Management Inc. sold 36,492 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $1.89, for a total value of $68,969.88. Following the completion of the transaction, the insider now owns 54,600 shares in the company, valued at approximately $103,194. This represents a 40.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.50% of the stock is owned by corporate insiders.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TARA. Oppenheimer & Co. Inc. bought a new stake in Protara Therapeutics during the first quarter worth about $40,000. Ikarian Capital LLC lifted its holdings in shares of Protara Therapeutics by 7.4% during the first quarter. Ikarian Capital LLC now owns 202,701 shares of the company’s stock valued at $813,000 after purchasing an additional 14,037 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Protara Therapeutics during the third quarter valued at approximately $60,000. Renaissance Technologies LLC boosted its position in shares of Protara Therapeutics by 77.8% in the 2nd quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after purchasing an additional 65,800 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Protara Therapeutics in the 2nd quarter worth approximately $161,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.